Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: phase II of the Friends of Cancer Research TMB Harmonization Project
Authors:
Open Access
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 32 (12) , 1626-1636
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca plc
- Genentech Inc
- Merck & Co Inc
- Bristol-Myers Squibb
- EMD Serono Inc
- Bristol-Myers Squibb Co Summit
- Chugai Pharmaceutical
This publication has 39 references indexed in Scilit:
- Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung CancerJAMA Oncology, 2017
- Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in CancerArchives of Pathology & Laboratory Medicine, 2017
- Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patientsNature Medicine, 2017
- Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working ProgressJournal of Thoracic Oncology, 2017
- Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burdenGenome Medicine, 2017
- Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor responseBiomarker Research, 2017
- PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison ProjectJournal of Thoracic Oncology, 2017
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)The Journal of Molecular Diagnostics, 2015
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013